A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

Abstract

Treatment with cladribine tablets significantly reduced relapse rates, the risk of disability progression, and MRI measures of disease activity at 96 weeks. The benefits need to be weighed against the risks. (ClinicalTrials.gov number, NCT00213135.)